AMGN heads into its August 4 earnings report with a 7% week-on-week rally, a sharp drop in short interest, and options traders moving cautiously more defensive — a setup where the longs are winning but the hedgers are watching.
The most striking move this week is the retreat by short sellers. Short interest has fallen 13% over the past week to 2.3% of free float, reversing a build that pushed the position above 2.7% in mid-July. That unwinding coincided almost exactly with the stock's breakout from $367 to $393. Borrow conditions tell the same story: availability is loose — roughly 4,790% of shares short are still available to lend, deep in "plenty of supply" territory — and cost to borrow is just 0.48%, even after a 41% week-on-week jump from an unusually low Monday reading. The ORTEX short score has eased to 36.3, down from 38.4 a week ago. Taken together, the lending market offers no constraint on new shorts, but active short sellers are clearly not pressing the position into the print.
Options positioning has shifted subtly but meaningfully toward caution. The put/call ratio has climbed to 0.83, above its 20-day average of 0.79 and running at a z-score of 1.35 — not extreme, but the highest it has been in several weeks. That moderate defensive tilt suggests some holders are buying downside protection ahead of Tuesday's results rather than adding calls. The 52-week range on the PCR runs from 0.62 to 1.11, so the current reading is well inside historical bounds — this looks like sensible pre-earnings hedging, not a crowded bearish setup.
The Street is split in a way that makes this week's rally awkward for consensus. The mean analyst price target is $357, roughly $36 below where the stock closed Tuesday. Barclays lifted its target to $360 and maintained Equal-Weight just this morning, while Morgan Stanley sits at $333 with the same neutral stance. UBS is the clearest bull, carrying a Buy with a $420 target after raising it earlier this month. The divide between bulls and neutrals is essentially a debate about pipeline execution. Bears flag near-term uptake risk for Uplizna, Tezspire, and Repatha, plus ongoing pricing pressure. Bulls point to the Horizon acquisition adding rare-disease diversification and a Q1 2026 beat on both sales and EPS as evidence the growth profile is intact. The PE stands at 17.1x, up about 1.4 turns over the past month as the price has run. The dividend yield factor scores in the 98th percentile — a reminder that Amgn's cash return story provides a floor for income-oriented holders even when growth catalysts are uncertain.
Compared to close peers, Amgn's week looks like a sector-wide lift with some individual outperformance. INCY led the group with a 10.7% weekly gain. REGN and GILD added around 3% each. BIIB was the laggard at just over 1%. Amgn's 7.3% move puts it near the top of the peer set — consistent with a stock where short covering contributed to the rally's speed, even if the absolute SI level was never high.
The last two earnings prints show a stock that doesn't move dramatically: a 2.2% gain the day after the May 2026 report, and a 2.4% drop after Q1 results in April. With the stock now sitting above every analyst's neutral-rated target but below the bull-case targets, Tuesday's call is essentially a referendum on whether management's pipeline commentary justifies the multiple expansion the market has already priced in over the past month.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
